Palatin Technologies Inc (PTN)
$0.87
+0.01
(+0.81%)▲
Performance
- $0.86$0.90$0.87
1.01%
Downside
Day's Volatility :4.2%
Upside
3.23%
- $0.68$5.65$0.87
21.84%
Downside
52 Weeks Volatility :87.96%
Upside
84.6%
Returns
| Period | Palatin Technologies Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -52.62% | 0.0% |
6 Months | -52.36% | 0.0% |
1 Year | -50.46% | 0.0% |
3 Years | -91.88% | -21.9% |
Highlights
Market Capitalization | 17.2M |
Book Value | -$0.01 |
Earnings Per Share (EPS) | -1.99 |
PEG Ratio | 0.0 |
Wall Street Target Price | 11.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -2378.75% |
Return On Assets TTM | -131.96% |
Return On Equity TTM | -623.2% |
Revenue TTM | 4.5M |
Revenue Per Share TTM | 0.31 |
Quarterly Revenue Growth YOY | -80.10000000000001% |
Gross Profit TTM | -18.2M |
EBITDA | -29.9M |
Diluted Eps TTM | -1.99 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.12 |
EPS Estimate Next Year | -1.64 |
EPS Estimate Current Quarter | -0.55 |
EPS Estimate Next Quarter | -0.26 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 1221.84%
Technicals Summary
Sell
Neutral
Buy
Palatin Technologies Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Palatin Technologies Inc | -37.63% | -52.36% | -50.46% | -91.88% | -95.87% |
 Regeneron Pharmaceuticals, Inc. | -12.04% | 12.88% | 20.22% | 83.33% | 233.83% |
 Novo Nordisk A/s | -12.51% | -3.33% | 18.42% | 134.08% | 356.57% |
 Alnylam Pharmaceuticals, Inc. | 4.79% | 91.82% | 69.4% | 35.85% | 250.43% |
 Vertex Pharmaceuticals Incorporated | -0.94% | 22.01% | 29.63% | 166.72% | 175.25% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Palatin Technologies Inc | NA | NA | 0.0 | -2.12 | -6.23 | -1.32 | NA | -0.01 |
Regeneron Pharmaceuticals, Inc. | 26.87 | 26.87 | 1.38 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.83 | 40.83 | 1.84 | 3.37 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.43 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.58 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Palatin Technologies Inc | Buy | $17.2M | -95.87% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.9B | 233.83% | 26.87 | 32.04% |
Novo Nordisk A/s | Buy | $535.2B | 356.57% | 40.83 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 250.43% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $125.1B | 175.25% | 32.84 | -4.74% |
Insights on Palatin Technologies Inc
Decreasing Revenue
Revenue is down for the last 3 quarters, 2.10M → 350.0K (in $), with an average decrease of 43.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -8.43M → -8.25M (in $), with an average increase of 2.2% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.5% return, outperforming this stock by 118.4%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 35.8% return, outperforming this stock by 127.7%
Company Information
palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy
Organization | Palatin Technologies Inc |
Employees | 30 |
CEO | Dr. Carl Spana Ph.D. |
Industry | Health Technology |
Discover More
Innovator Us Small Cap Power Buffer Etf - July
$0.87
+0.81%
First Trust Municipal High I
$0.87
+0.81%
Tiziana Life Sciences Plc
$0.87
+0.81%
Jinkosolar Holding Co., Ltd.
$0.87
+0.81%
Global Ship Lease Inc-cl A
$0.87
+0.81%
Lions Gate Entertainment Corp. Class B
$0.87
+0.81%
Innovator Growth-100 Power Buffer Etf - April
$0.87
+0.81%
Envela Corp
$0.87
+0.81%
Us Global Jets Etf
$0.87
+0.81%